Tag
Sun Pharmaceutical Industries Limited
4 articles
Sun Pharma Seeks Shareholder Approvals for ESOP and Acquisition
Sun Pharma proposes new ESOP 2026 plan for up to 12 million options using secondary market shares without dilution.
Company seeks enhanced borrowing limit of ₹700 billion and investment limit of ₹800
Sun Pharma Presents LEQSELVI Two-Year Alopecia Data
Sun Pharma filed regulatory disclosure for LEQSELVI (deuruxolitinib) two-year clinical data presentation at EADV Congress 2026.
Open-label extension study showed sustained efficacy with 93.9% of Week
Sun Pharma Shareholders Approve Promoter Group Reclassification
Sun Pharma shareholders approved reclassification of certain persons from Promoter Group to Public category on 26 September 2026.
The reclassification was conducted under Regulation 31A of SEBI Listin
Sun Pharma FY26 Revenue Growth 12% to ₹582 Billion
Sun Pharma reported FY26 revenue of ₹582.2 billion, a 12% YoY growth, with adjusted net profit at ₹124.0 billion.
The company is the 13th largest generics player in the US and maintains its position a